Krystal Biotech
KRYS
45 hedge funds and large institutions have $129M invested in Krystal Biotech in 2018 Q4 according to their latest regulatory filings, with 26 funds opening new positions, 12 increasing their positions, 4 reducing their positions, and 4 closing their positions.
550% more first-time investments, than exits
New positions opened: 26 | Existing positions closed: 4
200% more repeat investments, than reductions
Existing positions increased: 12 | Existing positions reduced: 4
171% more capital invested
Capital invested by funds: $47.6M → $129M (+$81.4M)
100% more funds holding in top 10
Funds holding in top 10: 1 → 2 (+1)
96% more funds holding
Funds holding: 23 → 45 (+22)
18.28% more ownership
Funds ownership: 24.75% → 43.03% (+18%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
BBA
Baker Bros. Advisors
New York
|
+$14M |
| 2 |
GPP
Great Point Partners
Greenwich,
Connecticut
|
+$10.3M |
| 3 |
Citadel Advisors
Miami,
Florida
|
+$7.01M |
| 4 |
RG
Redmile Group
San Francisco,
California
|
+$6.8M |
| 5 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$6.35M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCP
Tourbillon Capital Partners
New York
|
-$2.48M |
| 2 |
JP Morgan Chase
New York
|
-$731K |
| 3 |
Deutsche Bank
Frankfurt Am Main Ge,
Germany
|
-$403K |
| 4 |
Renaissance Technologies
New York
|
-$184K |
| 5 |
TRCT
Tower Research Capital (TRC)
New York
|
-$31.1K |
KRYS Hedge Fund Activity: Q4 2018 in Review
45 of the 4,505 institutional investors tracked by Wall St. Rank reported a position in Krystal Biotech (KRYS) for Q4 2018, worth a combined $129M — up 171% from $47.6M a quarter earlier.
Buyers outnumbered sellers: 26 funds opened new KRYS positions and 4 closed out — a net gain of 22 holders — while 12 added to existing stakes and 4 trimmed.
The largest buyer was Baker Bros. Advisors, adding an estimated $14M. The largest seller was Tourbillon Capital Partners, exiting entirely with an estimated $2.48M sold.
- 45 institutional investors held Krystal Biotech (KRYS) as of Q4 2018, up from 23 in Q3 2018.
- Funds reported $129M of Krystal Biotech stock for Q4 2018, up 171% quarter-over-quarter.
- 26 funds opened new Krystal Biotech positions in Q4 2018 and 4 closed out, a net change of +22 holders.
- The largest Krystal Biotech buyer in Q4 2018 was Baker Bros. Advisors, an estimated $14M added.
- The largest Krystal Biotech seller in Q4 2018 was Tourbillon Capital Partners, an estimated $2.48M sold.
Based on aggregated 13F filings for Q4 2018.